CD19 and diffuse large B-cell lymphoma: Tafasitamab, a CD19 monoclonal antibody with optimized target affinity and an engineered Fc portion to enhance antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively), led to CR rates of around 40% in R/R DLBCL.